EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSDLAG00005031355
Gene Symbol: MAP3K8
1 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSDLAG00005007150
Gene Symbol: MAP3K9
1 Cross references
195 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSDLAG00005032847
Gene Symbol: MGLL
1 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSDLAG00005025176
Gene Symbol: MLNR
1 Cross references
172 Possible Orthologues:

Natriuretic Peptide Receptor 1a

Ensembl ID : ENSDLAG00005035119
Gene Symbol: NPR1A
1 Cross references
194 Possible Orthologues:

Neuropeptide Y Receptor Y2, Like

Ensembl ID : ENSDLAG00005002529
Gene Symbol: NPY2RL
1 Cross references
176 Possible Orthologues:

Neuropeptide Y Receptor Y4

Ensembl ID : ENSDLAG00005029763
Gene Symbol: NPY4R
1 Cross references
137 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSDLAG00005029105
Gene Symbol: NTRK2
1 Cross references
208 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSDLAG00005010055
Gene Symbol: NTRK3
1 Cross references
183 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSDLAG00005020387
Gene Symbol: NTRK3
1 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSDLAG00005009140
Gene Symbol: NTRK1
1 Cross references
200 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSDLAG00005009848
Gene Symbol: NTRK2B
1 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).